Day One Biopharmaceuticals, Inc. (DAWN) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
5.05
↑+59% vs avg
5yr avg: 3.17
30Y Low2.2·High4.2
ROE
↑
-22.7%
↓+40% vs avg
5yr avg: -38.2%
30Y Low-212%·High-22%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
DAWN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Day One Biopharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $964M | $1.2B | $1.2B | $1.4B | $1.0B | — | — |
| Enterprise Value | $2.0B | $769M | $1.1B | $934M | $1.3B | $760M | — | — |
| P/E Ratio → | -20.70 | — | — | — | — | — | — | — |
| P/S Ratio | 14.06 | 6.09 | 9.04 | — | — | — | — | — |
| P/B Ratio | 5.05 | 2.18 | 2.36 | 3.36 | 4.24 | 3.71 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
DAWN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.86 | 8.11 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
DAWN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Day One Biopharmaceuticals, Inc. earns an operating margin of -80.8%. Operating margins have expanded from -165.7% to -80.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -22.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.1% | 89.1% | 96.0% | — | — | — | — | — |
| Operating Margin | -80.8% | -80.8% | -165.7% | — | — | — | — | — |
| Net Profit Margin | -67.8% | -67.8% | -72.8% | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -22.7% | -22.7% | -22.5% | -55.7% | -46.4% | -43.5% | -211.7% | — |
| ROA | -19.7% | -19.7% | -19.9% | -52.1% | -44.5% | -42.1% | -111.0% | -46.2% |
| ROIC | -30.5% | -30.5% | -65.6% | -85.0% | -90.1% | — | — | — |
| ROCE | -26.7% | -26.7% | -50.8% | -60.7% | -47.9% | -44.8% | -40.0% | -58.9% |
DAWN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $197M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.44 | -0.24 | -0.66 | -0.25 | -1.01 | -1.00 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -1460.43 | -7.18 |
Net cash position: cash ($197M) exceeds total debt ($3M)
DAWN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Day One Biopharmaceuticals, Inc.'s current ratio of 8.02x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 12.72x to 8.02x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.02 | 8.02 | 7.66 | 12.72 | 20.94 | 33.43 | 22.58 | 13.53 |
| Quick Ratio | 7.91 | 7.91 | 7.61 | 12.72 | 20.94 | 33.43 | 22.58 | 13.53 |
| Cash Ratio | 7.29 | 7.29 | 7.24 | 12.42 | 20.60 | 32.84 | 21.91 | 13.52 |
| Asset Turnover | — | 0.31 | 0.23 | — | — | — | — | — |
| Inventory Turnover | 2.72 | 2.72 | 1.59 | — | — | — | — | — |
| Days Sales Outstanding | — | 61.69 | 38.61 | — | — | — | — | — |
DAWN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Day One Biopharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $103M | $94M | $80M | $65M | $62M | $62M | $62M |
Peer Comparison
Compare DAWN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 DAWNYou | $2B | -20.7 | — | — | 89.1% | -80.8% | -22.7% | -30.5% | — |
 KURA | $840M | -3.0 | — | — | 99.9% | -449.9% | -94.8% | -188.5% | — |
 TGTX | $7B | 15.2 | 55.7 | — | 83.6% | 20.0% | 102.8% | 16.4% | 2.1 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 KYMR | $7B | -23.4 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ERAS | $3B | -15.8 | — | — | — | — | -43.7% | -39.2% | — |
 NVCR | $2B | -13.5 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 MGNX | $191M | -2.6 | — | — | — | -48.7% | -86.9% | -1879.3% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See DAWN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DAWN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DAWN vs KURA
Side-by-side business, growth, and profitability comparison vs Kura Oncology, Inc..
Start ComparisonDAWN — Frequently Asked Questions
Quick answers to the most common questions about buying DAWN stock.
What is Day One Biopharmaceuticals, Inc.'s P/E ratio?
Day One Biopharmaceuticals, Inc.'s current P/E ratio is -20.7x. This places it at the 50th percentile of its historical range.
What is Day One Biopharmaceuticals, Inc.'s ROE?
Day One Biopharmaceuticals, Inc.'s return on equity (ROE) is -22.7%. The historical average is -67.1%.
Is DAWN stock overvalued?
Based on historical data, Day One Biopharmaceuticals, Inc. is trading at a P/E of -20.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Day One Biopharmaceuticals, Inc.'s profit margins?
Day One Biopharmaceuticals, Inc. has 89.1% gross margin and -80.8% operating margin.